Get the Stockscreener App
8.65
2.26%
-0.20
After Hours:
8.65
Climb Bio Inc stock is traded at $8.65, with a volume of 830.19K.
It is down -2.26% in the last 24 hours and up +23.04% over the past month.
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
See More
Previous Close:
$8.85
Open:
$9.18
24h Volume:
830.19K
Relative Volume:
1.38
Market Cap:
$413.19M
Revenue:
-
Net Income/Loss:
$-59.85M
P/E Ratio:
-9.7663
EPS:
-0.8857
Net Cash Flow:
$-54.54M
1W Performance:
+21.83%
1M Performance:
+23.04%
6M Performance:
+345.88%
1Y Performance:
+536.03%
1-Day Range:
$8.17
$9.18
1-Week Range:
$7.09
$9.25
52-Week Range:
$1.13
$9.25
Climb Bio Inc Stock (CLYM) Company Profile
Name
Climb Bio Inc
Sector
Industry
Phone
1-866-857-2596
Address
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
8.65 | 422.75M | 0 | -59.85M | -54.54M | -0.8857 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Initiated | B. Riley Securities | Buy |
| Mar-18-26 | Initiated | Truist | Buy |
| Mar-11-26 | Initiated | Raymond James | Strong Buy |
| Mar-05-26 | Initiated | Wedbush | Outperform |
| Feb-13-26 | Initiated | Piper Sandler | Overweight |
| Oct-16-25 | Initiated | William Blair | Outperform |
| Oct-13-25 | Initiated | H.C. Wainwright | Buy |
| Aug-15-25 | Initiated | Robert W. Baird | Outperform |
| Jun-06-25 | Initiated | Oppenheimer | Outperform |
| May-22-25 | Initiated | BTIG Research | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
View All
Climb Bio Inc Stock (CLYM) Latest News
CLYM Initiated Coverage by Mizuho -- Rating Set to Outperform - GuruFocus
Mizuho Securities Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $18 - Moomoo
Mizuho initiates Climb Bio stock coverage with outperform rating By Investing.com - Investing.com Australia
Mizuho initiates Climb Bio stock coverage with outperform rating - Investing.com
Climb Bio (CLYM) price target increased by 34.43% to 15.67 - MSN
CLYM Options Volatility — NASDAQ:CLYM - TradingView — Track All Markets
CLYM Options Chain — NASDAQ:CLYM - TradingView — Track All Markets
[PRE 14A] Climb Bio, Inc. Preliminary Proxy Statement - Stock Titan
Piper Sandler Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23 - Moomoo
CLYM Stock Price, Quote & Chart | CLIMB BIO INC (NASDAQ:CLYM) - ChartMill
Climb Bio’s (CLYM) “Buy” Rating Reaffirmed at BTIG Research - Defense World
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 - Sahm
Income Plays: Does Climb Bio Inc offer margin of safety2026 Trade Ideas & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Climb Bio, Inc. to hold live R and D webcast on Budoprutug and CD19 opportunity - Traders Union
Growth Value: Is Climb Bio Inc currently under institutional pressure2026 Sector Moves & Technical Buy Zone Confirmation - baoquankhu1.vn
CLYM: BTIG Reiterates Buy Rating with $8 Target Price | CLYM Sto - GuruFocus
CLYM: BTIG Reiterates Buy Rating with $8 Target Price | CLYM Stock News - GuruFocus
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy - Sahm
Climb Bio’s budoprutug receives FDA fast track for kidney disease By Investing.com - Investing.com Australia
BTIG reiterates Buy on Climb Bio stock after FDA Fast Track nod - Investing.com Canada
BTIG reiterates Buy on Climb Bio stock after FDA Fast Track nod By Investing.com - Investing.com South Africa
FDA grants fast track status to Climb Bio’s kidney disease drug By Investing.com - Investing.com South Africa
FDA grants fast track status to Climb Bio’s kidney disease drug - Investing.com India
Climb Bio (stock code: CLYM) announced today that the U.S. Food and Drug Administration (FDA) has granted its candidate drug Budoprutug Fast Track designation for the treatment of primary membranous nephropathy. - Bitget
Climb Bio Announces FDA Fast Track Designation For Budoprutug For The Treatment Of Primary Membranous Nephropathy - TradingView — Track All Markets
Climb Bio Announces FDA Fast Track Designation for - GlobeNewswire
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - Dailyhunt
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.
Climb Bio, Inc. 8-K Filing Details: Company Information, Address, and Stock Exchange Listing (April 2026) - Minichart
Climb Bio announces departure of finance SVP and appointment of new accounting officer By Investing.com - Investing.com South Africa
Climb Bio announces departure of finance SVP and appointment of new accounting officer - Investing.com
Climb Bio's recently appointed CFO is unlikely to make a significant impact—what truly matters is the clinical data. - Bitget
Climb Bio Consolidates Financial Leadership After SVP Departure - TipRanks
Climb Bio (CLYM) consolidates CFO and principal accounting officer roles - Stock Titan
Piper Sandler initiates coverage of Climb Bio (CLYM) with overweight recommendation - MSN
Climb Bio, Inc. (NASDAQ:CLYM) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Climb Bio, Inc.Common Stock (NQ: CLYM - The Chronicle-Journal
Climb Bio (NASDAQ:CLYM) Raised to Strong-Buy at B. Riley Financial - MarketBeat
B Riley Securities initiates coverage of Climb Bio (CLYM) with buy recommendation - MSN
B. Riley Securities Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $26 - Moomoo
B. Riley Financial Initiates Coverage on Climb Bio (NASDAQ:CLYM) - MarketBeat
B.Riley initiates Climb Bio stock with buy rating on kidney drug potential - Investing.com
B.Riley initiates Climb Bio stock with buy rating on kidney drug potential By Investing.com - Investing.com Australia
Climb Bio Inc Stock (CLYM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):